BCL2 and breast cancer: In conclusion, in the present study, we have shown, to the best of our knowledge for the first time, that by combination of three parameters: BCL-2 positivity, low topoisomerase IIα expression and high microvessel density, it is possible to identify subgroups of BC patients with very good prognosis after adjuvant anthracycline-based chemotherapy.